Decrease of in Vitro Serum Protein Binding of Salicylate in Rheumatoid Arthritis

Overview

Journal Eur J Drug Metab Pharmacokinet

Date 1984 Apr 1

PMID 6745302

Citations 4

Authors

P Netter

C Monot

M C Stalars

J M Mur

R J Royer

G Faure

J Pourel

J Martin

A Gaucher

Affiliations

Soon will be listed here.

Abstract

Free and bound fractions of salicylates were separated by equilibrium dialysis and measured by spectrofluorimetry in 27 patients with rheumatoid arthritis and in 16 controls. The results showed that in patients with rheumatoid arthritis, the binding of salicylate to proteins decreased in an overproportional manner with the decrease of serum albumin concentrations. This phenomenon was linked with the severity of the inflammatory syndrome. The saturation binding capacity per unit of protein concentration was lower in the patients suffering from active forms of the condition, a finding which suggests that the changes observed are not due only to quantitative changes in the serum albumins. This study confirms the importance of determining free salicylate concentrations in the treatment of patients with inflammatory diseases.

Citing Articles

Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells.

Lapicque F, Vergne P, Jouzeau J, Loeuille D, Gillet P, Vignon E Clin Pharmacokinet. 2000; 39(5):369-82.

PMID: 11108435 DOI: 10.2165/00003088-200039050-00005.

Protein binding and stereoselectivity of nonsteroidal anti-inflammatory drugs.

Lapicque F, Muller N, Payan E, Dubois N, Netter P Clin Pharmacokinet. 1993; 25(2):115-23.

PMID: 8403735 DOI: 10.2165/00003088-199325020-00004.

Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid.

Bertin P, Lapicque F, Payan E, Rigaud M, Bailleul F, Jaeger S Eur J Clin Pharmacol. 1994; 46(1):3-7.

PMID: 8005184 DOI: 10.1007/BF00195907.

Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.

Netter P, Bannwarth B Clin Pharmacokinet. 1989; 17(3):145-62.

PMID: 2680211 DOI: 10.2165/00003088-198917030-00002.

References

Tillement J, Lhoste F, Giudicelli J . Diseases and drug protein binding. Clin Pharmacokinet. 1978; 3(2):144-54. DOI: 10.2165/00003088-197803020-00004. View

WOSILAIT W . Theoretical analysis of the binding of salicylate by human serum albumin: the relationship between free and bound drug and therapeutic levels. Eur J Clin Pharmacol. 1976; 9(4):285-90. DOI: 10.1007/BF00561662. View

Wallace S, Brodie M . Decreased drug binding in serum from patients with chronic hepatic disease. Eur J Clin Pharmacol. 1976; 09(5-6):429-32. DOI: 10.1007/BF00606560. View

Wallace S, Whiting B . Factors affecting drug binding in plasma of elderly patients. Br J Clin Pharmacol. 1976; 3(2):327-30. PMC: 1428869. DOI: 10.1111/j.1365-2125.1976.tb00611.x. View

Monot C, Netter P, Stalars M, Martin J, Royer R, Gaucher A . Difficulties in applying the Scatchard model of ligand binding to proteins--proposal of new mathematical tools--application to salicylates. J Pharm Sci. 1983; 72(1):35-41. DOI: 10.1002/jps.2600720109. View

Borga O, Cederlof I, Ringberger V, Norlin A . Protein binding of salicylate in uremic and normal plasma. Clin Pharmacol Ther. 1976; 20(4):464-75. DOI: 10.1002/cpt1976204464. View

WINDORFER A, Karitzky D, Gasteiger U, Stehr K . Investigations on salicylate protein binding in newborns and infants. Eur J Pediatr. 1978; 127(3):163-72. DOI: 10.1007/BF00442057. View

Pachman L, Olufs R, PROCKNAL J, Levy G . Pharmacokinetic monitoring of salicylate therapy in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1979; 22(8):826-31. DOI: 10.1002/art.1780220804. View

Trnavska Z, Trnavsky K . Characterization of salicylate binding to synovial fluid and plasma protein in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1980; 18(5):403-6. DOI: 10.1007/BF00636793. View

10.

Poe T, Mutchie K, Saunders G, HANISSIAN A, Sotello C . Total and free salicylate concentrations in juvenile rheumatoid arthritis. J Rheumatol. 1980; 7(5):717-23. View

11.

Levy G . Clinical pharmacokinetics of aspirin. Pediatrics. 1978; 62(5 Pt 2 Suppl):867-72. View

12.

Perrin J, Vallner J, Wold S . An unbiased method for estimating binding parameters in a non-cooperative binding process. Biochim Biophys Acta. 1974; 371(2):482-90. DOI: 10.1016/0005-2795(74)90044-0. View

13.

Ekstrand R, Alvan G, Borga O . Concentration dependent plasma protein binding of salicylate in rheumatoid patients. Clin Pharmacokinet. 1979; 4(2):137-43. DOI: 10.2165/00003088-197904020-00006. View

14.

ZAROSLINSKI J, Keresztes-Nagy S, MAIS R, OESTER Y . Effect of temperature on the binding of salicylate by human serum albumin. Biochem Pharmacol. 1974; 23(12):1767-76. DOI: 10.1016/0006-2952(74)90403-1. View

15.

Cockel R, Kendall M, Becker J, HAWKINS C . Serum biochemical values in rheumatoid disease. Ann Rheum Dis. 1971; 30(2):166-70. PMC: 1005745. DOI: 10.1136/ard.30.2.166. View

16.

Wanwimolruk S, Birkett D, Brooks P . Protein binding of some non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Clin Pharmacokinet. 1982; 7(1):85-92. DOI: 10.2165/00003088-198207010-00005. View

17.

Vallner J, Perrin J, Wold S . Comparison of graphical and computerized methods for calculating binding parameters for two strongly bound drugs to human serum albumin. J Pharm Sci. 1976; 65(8):1182-7. DOI: 10.1002/jps.2600650813. View

18.

Reynolds R, Cluff L . Interaction of serum and sodium salicylate: changes during acute infection and its influence on pharmacological activity. Bull Johns Hopkins Hosp. 1960; 107:278-90. View

19.

Behm H, Wagner J . Parabolic equation relating free and total drug concentrations in cases of nonlinear plasma protein binding. J Pharm Sci. 1981; 70(7):802-4. DOI: 10.1002/jps.2600700725. View

20.

Perez-Mateo M, Erill S . Protein binding of salicylate and quinidine in plasma from patients with renal failure, chronic liver disease and chronic respiratory insufficiency. Eur J Clin Pharmacol. 1977; 11(3):225-31. DOI: 10.1007/BF00606415. View